Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
PLYMOUTH, Minn., Oct. 24, 2016 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the third quarter 2016 after the close of trading on Thursday, November 3, 2016. The Company’s management team will host a corresponding conference call beginning at 3:30pm CT/4:30pm ET to discuss the financial results and recent business developments.
Individuals interested in listening to the conference call may do so by dialing (877) 930-5751 for domestic callers or (253) 336-7277 for international callers, using Conference ID: 94548883. To listen to a live webcast, please visit the investor relations section of the Entellus Medical website at: www.entellusmedical.com.
The webcast replay will be available on the Entellus Medical website following the completion of the call.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. The Entellus Medical platform of products provide effective and easy-to-use solutions to simplify everything from diagnosis and patient selection, to complex case revisions and post-operative care. Entellus Medical’s three core product lines, XprESS™ Multi-Sinus Dilation Systems, MiniFESS™ Surgical Instruments, and FocESS™ Imaging & Navigation, combine to enable ENT physicians to conveniently and comfortably perform a broad range of procedures in the office and simplify OR based treatment. Entellus Medical is committed to broadening its product portfolios with high-quality and purposeful innovations for the global ENT market. For more information, please visit the Company's website at www.entellusmedical.com.
Contact: Lynn Pieper Lewis 415-937-5402 [email protected]
